Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Larimar Therapeutics Inc’s stock clocked out at $2.91, up 9.40% from its previous closing price of $2.66. In other words, the price has increased by $9.40 from its previous closing price. On the day, 1.87 million shares were traded.
Ratios:
To gain a deeper understanding of LRMR’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.48 and its Current Ratio is at 7.48. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Truist on January 29, 2025, initiated with a Buy rating and assigned the stock a target price of $18.
On October 03, 2024, Wedbush started tracking the stock assigning a Outperform rating and target price of $22.Wedbush initiated its Outperform rating on October 03, 2024, with a $22 target price.
Stock Price History:
Over the past 52 weeks, LRMR has reached a high of $11.20, while it has fallen to a 52-week low of $1.61. The 50-Day Moving Average of the stock is 34.47%, while the 200-Day Moving Average is calculated to be -36.46%.
Shares Statistics:
A total of 64.03M shares are outstanding, with a floating share count of 36.46M. Insiders hold about 43.06% of the company’s shares, while institutions hold 57.92% stake in the company.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 6.0 analysts currently analyzing and rating the stock of Larimar Therapeutics Inc (LRMR).The consensus estimate for the next quarter is -$0.51, with high estimates of -$0.47 and low estimates of -$0.56.
Analysts are recommending an EPS of between -$1.83 and -$2.12 for the fiscal current year, implying an average EPS of -$1.95. EPS for the following year is -$1.75, with 6.0 analysts recommending between -$0.86 and -$2.57.
